

# Theodore E Warkentin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6246133/publications.pdf>

Version: 2024-02-01

378  
papers

35,528  
citations

2975

93  
h-index

3732

179  
g-index

394  
all docs

394  
docs citations

394  
times ranked

14602  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. <i>New England Journal of Medicine</i> , 1995, 332, 1330-1336.	27.0	2,664
2	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 2092-2101.	27.0	1,765
3	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. <i>Chest</i> , 2001, 119, 64S-94S.	0.8	1,275
4	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-1708.	1.4	976
5	Temporal Aspects of Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2001, 344, 1286-1292.	27.0	925
6	Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 759-765.	3.8	916
7	A 14-year study of heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 1996, 101, 502-507.	1.5	872
8	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2008, 133, 340S-380S.	0.8	783
9	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. <i>Chest</i> , 2004, 126, 311S-337S.	0.8	766
10	Heparin-induced thrombocytopenia and cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 76, 2121-2131.	1.3	638
11	Heparin-induced thrombocytopenia: pathogenesis and management. <i>British Journal of Haematology</i> , 2003, 121, 535-555.	2.5	492
12	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 3360-3392.	5.2	448
13	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. <i>Annals of Internal Medicine</i> , 2001, 135, 502.	3.9	429
14	The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia. <i>Annals of Internal Medicine</i> , 1997, 127, 804.	3.9	427
15	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2012, 120, 4160-4167.	1.4	393
16	Dalteparin versus Unfractionated Heparin in Critically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 364, 1305-1314.	27.0	382
17	The unique characteristics of COVID-19 coagulopathy. <i>Critical Care</i> , 2020, 24, 360.	5.8	366
18	Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 132-135.	3.4	352

#	ARTICLE	IF	CITATIONS
19	Quantitative interpretation of optical density measurements using PF4-dependent enzyme immunoassays. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1304-1312.	3.8	333
20	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	3.8	325
21	Autoimmune heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2099-2114.	3.8	319
22	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 2518.	3.8	287
23	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016, 375, 1937-1945.	27.0	278
24	Antiplatelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. <i>Blood</i> , 2005, 106, 3791-3796.	1.4	271
25	Heparin-Induced Thrombocytopenia Associated with Fondaparinux. <i>New England Journal of Medicine</i> , 2007, 356, 2653-2655.	27.0	265
26	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. <i>Translational Research</i> , 2005, 146, 341-346.	2.3	261
27	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. <i>Blood</i> , 2008, 111, 4871-4879.	1.4	260
28	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. <i>Blood</i> , 2006, 108, 2937-2941.	1.4	259
29	Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. <i>Lancet, The</i> , 1992, 340, 35-37.	13.7	254
30	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Blood</i> , 2021, 138, 2256-2268.	1.4	228
31	Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1666-1673.	3.8	224
32	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	1.4	219
33	Bivalirudin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 830-839.	3.4	211
34	Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. <i>Journal of Critical Care</i> , 2005, 20, 348-353.	2.2	210
35	What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. <i>American Journal of Hematology</i> , 2007, 82, 1037-1043.	4.1	209
36	The direct thrombin inhibitor hirudin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 819-829.	3.4	207

#	ARTICLE	IF	CITATIONS
37	Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. <i>Blood</i> , 2001, 98, 1842-1846.	1.4	198
38	Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. <i>Blood</i> , 2005, 105, 139-144.	1.4	196
39	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 188-194.	1.4	190
40	Heparin-induced thrombocytopenia and cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 76, 638-648.	1.3	187
41	Optical Densities Reduce Odds of Heparin-induced Thrombocytopenia Over-diagnosis. <i>American Journal of Medicine</i> , 2012, 125, 3-4.	1.5	185
42	Heparin-induced thrombocytopenia in intensive care patients. <i>Critical Care Medicine</i> , 2007, 35, 1165-1176.	0.9	179
43	Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. <i>British Journal of Haematology</i> , 1993, 84, 322-328.	2.5	175
44	Heparin-induced skin lesions. <i>British Journal of Haematology</i> , 1996, 92, 494-497.	2.5	175
45	Heparin-induced thrombocytopenia: a historical perspective. <i>Blood</i> , 2008, 112, 2607-2616.	1.4	172
46	Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine <sup>®</sup> SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. <i>Transfusion</i> , 2009, 49, 1171-1177.	1.6	172
47	Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. <i>Transfusion Medicine Reviews</i> , 2003, 17, 272-286.	2.0	171
48	Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis. <i>Chest</i> , 2013, 144, 1207-1215.	0.8	171
49	Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 2004, 110, e454-8.	1.6	165
50	Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. <i>Blood</i> , 2003, 101, 3049-3051.	1.4	164
51	Drug-Induced Immune-Mediated Thrombocytopenia – From Purpura to Thrombosis. <i>New England Journal of Medicine</i> , 2007, 356, 891-893.	27.0	161
52	Studies of the immune response in heparin-induced thrombocytopenia. <i>Blood</i> , 2009, 113, 4963-4969.	1.4	157
53	Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 30-36.	3.8	157
54	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2386-2393.	2.4	156

#	ARTICLE	IF	CITATIONS
55	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 720-728.	27.0	156
56	A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. <i>American Journal of Medicine</i> , 2008, 121, 632-636.	1.5	154
57	The epitope specificity of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1996, 95, 161-167.	2.5	152
58	Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. <i>Blood</i> , 2017, 130, 1104-1113.	1.4	152
59	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2498-2500.	3.8	150
60	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-8.	1.4	150
61	Laboratory diagnosis of immune heparin-induced thrombocytopenia. <i>Psychophysiology</i> , 2003, 2, 148-57.	1.1	150
62	New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2005, 127, 35S-45S.	0.8	145
63	A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 1999, 104, 442-447.	2.5	144
64	Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Transfusion Medicine Reviews</i> , 2006, 20, 259-272.	2.0	142
65	Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 2013, 27, 137-145.	2.0	141
66	Clinical presentation of heparin-induced thrombocytopenia. <i>Seminars in Hematology</i> , 1998, 35, 9-16; discussion 35-6.	3.4	140
67	The platelet serotonin-release assay. <i>American Journal of Hematology</i> , 2015, 90, 564-572.	4.1	138
68	Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. <i>Blood</i> , 2014, 123, 3651-3654.	1.4	132
69	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 958-964.	3.4	130
70	How I Diagnose and Manage HIT. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 143-149.	2.5	129
71	HEPARIN-INDUCED THROMBOCYTOPENIA: A Ten-Year Retrospective. <i>Annual Review of Medicine</i> , 1999, 50, 129-147.	12.2	128
72	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2019, 8, 728.	2.4	128

#	ARTICLE	IF	CITATIONS
73	Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology American Society of Hematology Education Program, 2003, 2003, 497-519.	2.5	127
74	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin release assay: a 30-month, 16-patient case series. Journal of Thrombosis and Haemostasis, 2011, 9, 2389-2396.	3.8	127
75	A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	2.5	125
76	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood, 2021, 138, 299-303.	1.4	125
77	Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia. Archives of Pathology and Laboratory Medicine, 2002, 126, 1415-1423.	2.5	124
78	Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. Translational Research, 1992, 120, 371-9.	2.3	124
79	Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Practice and Research in Clinical Haematology, 2004, 17, 105-125.	1.7	123
80	Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome. Chest, 2005, 127, 1857-1861.	0.8	121
81	High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Review of Hematology, 2019, 12, 685-698.	2.2	121
82	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care, 2010, 25, 287-293.	2.2	117
83	Heparin-Induced Thrombocytopenia. Annual Review of Medicine, 1989, 40, 31-44.	12.2	112
84	The temporal profile of the anti-PF4/heparin immune response. Blood, 2009, 113, 4970-4976.	1.4	109
85	A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2013, 11, 169-176.	3.8	109
86	Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thrombosis Research, 2003, 110, 73-82.	1.7	107
87	An Overview of the Heparin-Induced Thrombocytopenia Syndrome. Seminars in Thrombosis and Hemostasis, 2004, 30, 273-283.	2.7	106
88	Failure of Anticoagulant Thromboprophylaxis. Critical Care Medicine, 2015, 43, 401-410.	0.9	106
89	Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thrombosis Research, 2008, 122, 211-220.	1.7	105
90	Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia. Transfusion Medicine Reviews, 1996, 10, 249-258.	2.0	104

#	ARTICLE	IF	CITATIONS
91	Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. <i>Blood</i> , 2021, 138, 1269-1277.	1.4	102
92	Delayed-Onset Heparin-Induced Thrombocytopenia and Cerebral Thrombosis after a Single Administration of Unfractionated Heparin. <i>New England Journal of Medicine</i> , 2003, 348, 1067-1069.	27.0	101
93	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. <i>Blood</i> , 2015, 126, 597-603.	1.4	101
94	Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 107-110.	3.8	98
95	Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2002, 71, 50-52.	4.1	95
96	Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 129-144.	2.4	95
97	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. <i>Blood</i> , 2005, 106, 2921-2922.	1.4	94
98	Ischemic Limb Gangrene with Pulses. <i>New England Journal of Medicine</i> , 2015, 373, 642-655.	27.0	92
99	Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 1999, 62, 44-48.	4.1	90
100	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the Fcγ3R1a low responder (his131) gene in patients with heparin-induced thrombocytopenia. <i>Translational Research</i> , 1997, 130, 278-284.	2.3	88
101	HIT paradigms and paradoxes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 105-117.	3.8	88
102	Heparin-Induced Thrombocytopenia in Critically Ill Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 049-060.	2.7	87
103	Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. <i>Blood</i> , 1994, 84, 3691-9.	1.4	86
104	Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management. <i>Critical Care Medicine</i> , 2006, 34, 2898-2911.	0.9	84
105	Laboratory diagnosis of heparin-induced thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 15-25.	1.3	84
106	Heparin-induced thrombocytopenia: towards consensus. <i>Thrombosis and Haemostasis</i> , 1998, 79, 1-7.	3.4	84
107	Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 589-607.	2.2	83
108	How do we approach thrombocytopenia in critically ill patients?. <i>British Journal of Haematology</i> , 2017, 177, 27-38.	2.5	83

#	ARTICLE	IF	CITATIONS
109	Proposal of the Definition for COVID-19-Associated Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 191.	2.4	83
110	Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2001, 135, 589.	3.9	82
111	Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. <i>British Journal of Haematology</i> , 1990, 76, 387-394.	2.5	81
112	Fondaparinux: does it cause HIT? can it treat HIT?. <i>Expert Review of Hematology</i> , 2010, 3, 567-581.	2.2	81
113	Gastrointestinal Angiodysplasia and Aortic Stenosis. <i>New England Journal of Medicine</i> , 2002, 347, 858-859.	27.0	79
114	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. <i>Blood</i> , 2015, 125, 195-198.	1.4	78
115	Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1900-1907.	3.8	78
116	Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 25-43.	2.4	76
117	Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 149-156.	3.8	76
118	Think of HIT. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 408-414.	2.5	75
119	Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 428-435.	3.8	74
120	Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2025-2031.	3.8	74
121	Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. <i>Blood</i> , 2014, 123, 2485-2493.	1.4	74
122	Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1206-1210.	3.8	74
123	Heparin-Induced Thrombocytopenia in Patients with Ventricular Assist Devices: Are New Prevention Strategies Required?. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1633-1640.	1.3	72
124	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. <i>Thrombosis Research</i> , 2021, 204, 40-51.	1.7	72
125	Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of "spontaneous" HIT?. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1598-1600.	3.8	70
126	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. <i>Chest</i> , 2011, 140, 366-373.	0.8	69



#	ARTICLE	IF	CITATIONS
127	Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 813-822.	3.4	69
128	ISTH DIC subcommittee communication on anticoagulation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2138-2144.	3.8	69
129	Heparin-induced thrombocytopenia " therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2160-2167.	3.8	68
130	Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. <i>Thrombosis Research</i> , 2006, 117, 507-515.	1.7	66
131	Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. <i>Blood</i> , 2010, 115, 29-31.	1.4	65
132	Agents for the Treatment of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 755-775.	2.2	65
133	Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. <i>Blood</i> , 2013, 121, 2821-2827.	1.4	64
134	Improving Clinical Interpretation of the Anti-Platelet Factor 4/Heparin Enzyme-Linked Immunosorbent Assay for the Diagnosis of Heparin-Induced Thrombocytopenia Through the Use of Receiver Operating Characteristic Analysis, Stratum-Specific Likelihood Ratios, and Bayes Theorem. <i>Chest</i> , 2013, 144, 1269-1275.	0.8	63
135	Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 678-679.	3.8	62
136	Non-necrotizing heparin-induced skin lesions and the 4T score. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1483-1485.	3.8	62
137	Transient global amnesia associated with acute heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 1994, 97, 489-491.	1.5	61
138	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	1.6	61
139	Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1357-1361.	3.4	60
140	Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. <i>Chest</i> , 2013, 144, 848-858.	0.8	60
141	Reversing anticoagulants both old and new. <i>Canadian Journal of Anaesthesia</i> , 2002, 49, S11-25.	1.6	60
142	Bivalirudin: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1349-1371.	1.8	58
143	How I treat patients with a history of heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 128, 348-359.	1.4	56
144	Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL <sup>®</sup> HIT-Ab (PF4-H) ] for the diagnosis of immune heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2017, 153, 108-117.	1.7	56

#	ARTICLE	IF	CITATIONS
145	Heparin-induced thrombocytopenia: a clinicopathologic syndrome. <i>Thrombosis and Haemostasis</i> , 1999, 82, 439-47.	3.4	55
146	Heparin-Induced Thrombocytopenia: Real-World Issues. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 653-663.	2.7	53
147	Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. <i>Platelets</i> , 1999, 10, 319-326.	2.3	52
148	Heparin-Induced Thrombocytopenia Presenting as Bilateral Adrenal Hemorrhages. <i>New England Journal of Medicine</i> , 2015, 372, 492-494.	27.0	52
149	Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 504-512.	3.8	51
150	Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. <i>Platelets</i> , 2017, 28, 614-620.	2.3	51
151	Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery "spontaneous" HIT. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 499-501.	3.8	50
152	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 415-419.	3.8	50
153	Intraoperative Heparin Flushes and Subsequent Acute Heparin-induced Thrombocytopenia. <i>Anesthesiology</i> , 1998, 89, 1567-1569.	2.5	49
154	Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy</i> , 1999, 19, 181-195.	2.6	49
155	HITlights: A career perspective on heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2012, 87, S92-9.	4.1	48
156	Heparin-induced thrombocytopenia. <i>Current Opinion in Critical Care</i> , 2015, 21, 576-585.	3.2	47
157	Aspirin for Dual Prevention of Venous and Arterial Thrombosis. <i>New England Journal of Medicine</i> , 2012, 367, 2039-2041.	27.0	46
158	Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1071-1072.	3.4	44
159	Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. <i>Journal of Critical Care</i> , 2014, 29, 470.e7-470.e15.	2.2	44
160	High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. <i>Blood</i> , 2018, 132, 1345-1349.	1.4	44
161	No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 281-282.	3.8	43
162	Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. <i>American Heart Journal</i> , 2010, 160, 362-369.	2.7	43

#	ARTICLE	IF	CITATIONS
163	Serotoninâ€release assayâ€negative heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, 38-47.	4.1	43
164	Posttransfusion platelet count increments after ABOâ€compatible versus ABOâ€incompatible platelet transfusions in noncancer patients: an observational study. Transfusion, 2010, 50, 1552-1560.	1.6	42
165	The Role for Optical Density in Heparin-Induced Thrombocytopenia. Chest, 2015, 148, 55-61.	0.8	42
166	Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. Platelets, 2021, 32, 936-940.	2.3	42
167	Limitations of conventional treatment options for heparin-induced thrombocytopenia. Seminars in Hematology, 1998, 35, 17-25; discussion 35-6.	3.4	42
168	Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion, 2004, 44, 1361-1366.	1.6	41
169	The alloimmune thrombocytopenic syndromes. Transfusion Medicine Reviews, 1997, 11, 296-307.	2.0	40
170	The use of wellâ€characterized sera for the assessment of new diagnostic enzymeâ€immunoassays for the diagnosis of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2010, 8, 216-218.	3.8	40
171	Highâ€dose intravenous immunoglobulin to treat spontaneous heparinâ€induced thrombocytopenia syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 841-844.	3.8	40
172	Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin â€flushesâ€. Thrombosis and Haemostasis, 2007, 98, 1139-1140.	3.4	39
173	Delayedâ€onset HIT caused by lowâ€molecularâ€weight heparin manifesting during fondaparinux prophylaxis. American Journal of Hematology, 2008, 83, 876-878.	4.1	39
174	Heparin-Induced Thrombocytopenia in Critically Ill Patients. Critical Care Clinics, 2011, 27, 805-823.	2.6	39
175	Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood, 2015, 126, 486-493.	1.4	39
176	Performance characteristics of a rapid assay for antiâ€PF4/heparin antibodies: the particle immunofiltration assay. Journal of Thrombosis and Haemostasis, 2007, 5, 2308-2310.	3.8	38
177	The Approach to Heparin-Induced Thrombocytopenia. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 066-074.	2.1	37
178	Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2018, 378, 1845-1848.	27.0	37
179	Proposal of a twoâ€step process for the diagnosis of sepsisâ€induced disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis, 2019, 17, 1265-1268.	3.8	37
180	COVID-19 versus HIT hypercoagulability. Thrombosis Research, 2020, 196, 38-51.	1.7	37

#	ARTICLE	IF	CITATIONS
181	Investigation of human platelet alloantigens and glycoproteins using non-radioactive immunoprecipitation. <i>Journal of Immunological Methods</i> , 1993, 158, 77-85.	1.4	36
182	Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 894-896.	3.8	36
183	Management of heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2016, 23, 462-470.	2.5	36
184	Heparin, Low Molecular Weight Heparin, and Heparin-Induced Thrombocytopenia in the ICU. <i>Critical Care Clinics</i> , 2005, 21, 513-529.	2.6	35
185	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. <i>Thrombosis Research</i> , 2011, 128, 256-260.	1.7	35
186	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e544-e552.	4.6	34
187	When is HIT Really HIT?. <i>Annals of Thoracic Surgery</i> , 2007, 83, 21-23.	1.3	32
188	Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1243-1246.	3.8	32
189	Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1203-1212.	3.8	32
190	Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. <i>Blood</i> , 2017, 130, 1679-1682.	1.4	32
191	Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. <i>Expert Review of Hematology</i> , 2008, 1, 75-85.	2.2	31
192	Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Seminars in Hematology</i> , 2022, 59, 89-96.	3.4	31
193	Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. <i>Transfusion</i> , 2010, 50, 32-39.	1.6	30
194	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2022, 50, e80-e86.	0.9	30
195	Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. <i>Transfusion</i> , 2010, 50, 1722-1730.	1.6	29
196	Design of the rivaroxaban for heparin-induced thrombocytopenia study. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 485-492.	2.1	29
197	Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. <i>Cmaj</i> , 2014, 186, 929-933.	2.0	29
198	Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 678-683.	2.3	29

#	ARTICLE	IF	CITATIONS
199	Heparin-induced thrombocytopenia. <i>Cmaj</i> , 2021, 193, E736-E736.	2.0	29
200	Clinical Picture of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 21-66.	0.0	29
201	Who Is (Still) Getting HIT?. <i>Chest</i> , 2007, 131, 1620-1622.	0.8	28
202	Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. <i>Haematologica</i> , 2022, 107, 1219-1221.	3.5	28
203	Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 60-67.	2.1	27
204	Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit "overdiagnosis" in a patient with antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2011, 86, 188-191.	4.1	26
205	Pitfalls in the diagnosis of heparin-induced thrombocytopenia: A 6-year experience from a reference laboratory. <i>American Journal of Hematology</i> , 2015, 90, 629-633.	4.1	26
206	The alloimmune thrombocytopenic syndromes. <i>Transfusion Medicine Reviews</i> , 1997, 11, 296-307.	2.0	26
207	Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. <i>American Journal of Hematology</i> , 2004, 75, 56-62.	4.1	25
208	Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. <i>American Journal of Hematology</i> , 2005, 78, 188-192.	4.1	25
209	HIT: Lessons Learned. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 50-57.	0.3	25
210	The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. <i>Thrombosis and Haemostasis</i> , 2012, 108, 394-396.	3.4	25
211	Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1685-1695.	3.8	25
212	Platelet-activating anti-PF4 disorders: An overview. <i>Seminars in Hematology</i> , 2022, 59, 59-71.	3.4	25
213	An algorithm for resolving "indeterminate" test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1595-1597.	3.8	24
214	PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. <i>Journal of Critical Care</i> , 2011, 26, 223.e1-223.e9.	2.2	24
215	Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. <i>Transfusion</i> , 2012, 52, 529-536.	1.6	24
216	A practical approach to evaluating postoperative thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 776-783.	5.2	24

#	ARTICLE	IF	CITATIONS
217	Current agents for the treatment of patients with heparin-induced thrombocytopenia. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 405-412.	2.6	23
218	An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 525-531.	3.8	23
219	Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1435-1446.	3.8	23
220	So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. <i>Chest</i> , 2007, 132, 1108-1110.	0.8	22
221	HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1319-1322.	3.4	22
222	Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. <i>American Journal of Hematology</i> , 2016, 91, E327-9.	4.1	22
223	Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. <i>Transfusion</i> , 2019, 59, 1924-1933.	1.6	22
224	Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1677-1680.	3.4	22
225	Impact of the patient population on the risk for heparin-induced thrombocytopenia. <i>Blood</i> , 2000, 96, 1703-1708.	1.4	22
226	Contaminated Heparin. <i>New England Journal of Medicine</i> , 2008, 359, 1291-1293.	27.0	21
227	Immunoassays are not created equal. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1256-1259.	3.8	21
228	Acute Hepatic Necrosis and Ischemic Limb Necrosis. <i>New England Journal of Medicine</i> , 2012, 367, 879-881.	27.0	21
229	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver" the unrecognized provocateur of ischemic limb necrosis?. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 231-235.	3.8	21
230	Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: Influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1456-1463.	0.8	20
231	Frequency of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 67-116.	0.0	20
232	Microvascular Thrombosis and Ischaemic Limb Losses in Critically Ill Patients. <i>Hamostaseologie</i> , 2019, 39, 006-019.	1.9	19
233	Current Concepts in the Treatment of Immune Thrombocytopenia. <i>Drugs</i> , 1990, 40, 531-542.	10.9	18
234	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 1996, 93, 421-426.	2.5	18

#	ARTICLE	IF	CITATIONS
235	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. <i>British Journal of Haematology</i> , 1995, 91, 742-746.	2.5	17
236	Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 636-637.	3.8	17
237	Heparin-Induced Thrombocytopenia in the ICU. <i>Chest</i> , 2012, 142, 815-816.	0.8	17
238	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1973-1978.	3.8	17
239	Spontaneous Heparin-Induced Thrombocytopenia Presenting as Cerebral Venous Sinus Thrombosis. <i>Neurology: Clinical Practice</i> , 2021, 11, e929-e931.	1.6	17
240	Heparin-induced thrombocytopenia and its treatment. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 29-35.	2.1	16
241	Think of HIT When Thrombosis Follows Heparin. <i>Chest</i> , 2006, 130, 631-632.	0.8	16
242	Case report: Management of immediate post-cardiopulmonary bypass massive intra-cardiac thrombosis. <i>Canadian Journal of Anaesthesia</i> , 2007, 54, 461-466.	1.6	16
243	Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. <i>Chest</i> , 2018, 153, 1396-1404.	0.8	16
244	Heparin-induced thrombocytopenia-associated thrombosis: from arterial to venous to venous limb gangrene. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2128-2132.	3.8	16
245	Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. <i>Platelets</i> , 2020, 31, 124-127.	2.3	16
246	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 148-150.	3.8	15
247	Non-injection-site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. <i>American Journal of Hematology</i> , 2015, 90, 747-750.	4.1	15
248	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	2.0	15
249	Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1640-1645.	3.8	15
250	Heparin-Induced Thrombocytopenia and Vascular Surgery. <i>Acta Chirurgica Belgica</i> , 2004, 104, 257-265.	0.4	14
251	Transient Global Amnesia as the Presenting Feature of Heparin-Induced Thrombocytopenia. <i>Journal of Cardiac Surgery</i> , 2010, 25, 300-302.	0.7	14
252	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	2.1	14

#	ARTICLE	IF	CITATIONS
253	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 8-14.	3.4	14
254	Fc $\gamma$ RIIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1146-1153.	3.8	14
255	Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 253-260.	3.8	14
256	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. <i>Blood</i> , 2019, 133, 978-989.	1.4	14
257	High-dose IVIG plus cangrelor platelet anesthesia during urgent heparin-CPB in a patient with recent SRA-negative HIT thrombosis with persisting platelet-activating antibodies. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1060-1064.	2.3	14
258	Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies – distinguishing "signal" from "noise". <i>Thrombosis and Haemostasis</i> , 2008, 100, 523-524.	3.4	14
259	Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients. <i>British Journal of Haematology</i> , 2011, 154, 378-386.	2.5	13
260	Progressive, Fatal Thrombosis Associated With Heparin-Induced Thrombocytopenia After Cardiac Surgery Despite Therapeutic Anticoagulation With Argatroban: Potential Role for PTT and ACT Confounding. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1319-1321.	1.3	13
261	Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1868-1874.	3.4	12
262	Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. <i>Experimental Hematology and Oncology</i> , 2017, 6, 21.	5.0	12
263	Timeline of heparin-induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 493-502.	1.3	12
264	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	2.5	12
265	Symmetrical peripheral gangrene in critical illness. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103094.	1.0	12
266	Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2420-2422.	1.6	11
267	Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. <i>American Journal of Hematology</i> , 2011, 86, 603-606.	4.1	11
268	HIT: treatment easier, prevention harder. <i>Blood</i> , 2012, 119, 1099-1100.	1.4	11
269	The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia. <i>Transfusion</i> , 2015, 55, 1128-1134.	1.6	11
270	Ischemic Limb Gangrene with Pulses. <i>New England Journal of Medicine</i> , 2015, 373, 2385-2388.	27.0	11



#	ARTICLE	IF	CITATIONS
271	Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2649-2651.	2.8	11
272	The association between platelet transfusions and mortality in patients with critical illness. <i>Transfusion</i> , 2019, 59, 1962-1970.	1.6	11
273	Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. <i>Blood Advances</i> , 2020, 4, 5184-5193.	5.2	11
274	Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. <i>Hamostaseologie</i> , 2020, 40, 472-484.	1.9	11
275	Serotoninâ€release assayâ€positive but platelet factor 4â€dependent enzymeâ€immunoassay negative: HIT or not HIT ?. <i>American Journal of Hematology</i> , 2021, 96, 320-329.	4.1	11
276	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. <i>Thrombosis and Haemostasis</i> , 2022, 122, 304-307.	3.4	11
277	Heparin-induced thrombocytopenia. <i>Psychophysiology</i> , 2002, 1, 63-72.	1.1	11
278	Laboratory testing for VITT antibodies. <i>Seminars in Hematology</i> , 2022, 59, 80-88.	3.4	11
279	Spinal-cord concussion in frogs a study of reflex changes. <i>World Neurosurgery</i> , 1983, 20, 456-460.	1.3	10
280	Acute pancreatitis preceding thrombotic thrombocytopenic Purpura. <i>Haematologica</i> , 2007, 92, e94-e95.	3.5	10
281	Heydeâ€™s syndrome: From controversy to mainstream. <i>Thrombosis and Haemostasis</i> , 2010, 103, 251-253.	3.4	10
282	Scoring systems for heparin-induced thrombocytopenia (HIT): Whither now?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 437-438.	3.4	10
283	Demand on-demand testing for the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 140, 163-164.	1.7	10
284	Acute haemolysis, DIC and renal failure after transfusion of uncrossâ€matched blood during trauma resuscitation: illustrative case and literature review. <i>Transfusion Medicine</i> , 2018, 28, 319-325.	1.1	10
285	A comparative study of platelet factor 4â€enhanced platelet activation assays for the diagnosis of heparinâ€induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1096-1102.	3.8	10
286	Analysis of a nonsusceptible fraction with current status data. <i>Statistics in Medicine</i> , 2008, 27, 2715-2730.	1.6	9
287	HIT: more than just heparin. <i>Blood</i> , 2010, 115, 1664-1665.	1.4	9
288	IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2017, 152, 453-455.	0.8	9

#	ARTICLE	IF	CITATIONS
289	Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2019, 119, 941-951.	3.4	9
290	Spontaneous heparin-induced thrombocytopenia syndrome presenting as bilateral adrenal infarction after knee arthroplasty. <i>BMJ Case Reports</i> , 2019, 12, e232769.	0.5	9
291	<i>A</i> BO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. <i>Blood</i> , 2022, 140, 274-284.	1.4	9
292	A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1446-1449.	3.8	8
293	Immature Platelet Count. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2130-2132.	2.8	8
294	Rivaroxaban for treatment of HIT: A riveting first experience. <i>Thrombosis Research</i> , 2015, 135, 1-2.	1.7	8
295	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1402-1412.	3.8	8
296	Reversing Anticoagulant Therapy. <i>Current Drug Discovery Technologies</i> , 2012, 9, 143-149.	1.2	8
297	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – update on diagnosis and management considering different resources: Response to Comment from Yamada et al. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 542-543.	3.8	8
298	PF4-dependent immunoassays and inferential detection of HIT antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 232-234.	3.8	7
299	Current perspective of venous thrombosis in the upper extremity: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 237-238.	3.8	7
300	Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1067-1069.	3.8	7
301	The association between platelet activation and FcγRIIIa proteolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 885-887.	3.8	7
302	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012, 107, 998-1000.	3.4	7
303	4Ts scoring with hemofiltration or hemodialysis clotting. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 7-9.	1.6	7
304	Acute intraoperative HIT during heart surgery: Why so rare?. <i>Thrombosis Research</i> , 2016, 146, 110-112.	1.7	7
305	Symmetrical Peripheral Gangrene: Mechanisms for Limb Loss in the ICU in Patients With Retained Pulses. <i>Clinical Pulmonary Medicine</i> , 2018, 25, 61-66.	0.3	7
306	Maximum 24-hour platelet count fall: Metric for improving the diagnosis of heparin-induced thrombocytopenia among patients with intermediate probability 4Ts scores. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2018-2024.	3.8	7

#	ARTICLE	IF	CITATIONS
307	Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. <i>Blood Transfusion</i> , 2016, 14, 66-72.	0.4	7
308	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.9	7
309	Vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Seminars in Hematology</i> , 2022, 59, 57-58.	3.4	7
310	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4137-4146.	5.2	7
311	SARS-CoV-2 Infection in Patients with a History of VITT. <i>New England Journal of Medicine</i> , 2022, 387, 88-90.	27.0	7
312	Platelet Microparticle Generation Assay for Detection of HIT Antibodies: Advance, Retreat, or Too Soon to Tell?. <i>Thrombosis Research</i> , 2014, 133, 957-958.	1.7	6
313	Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 131.	0.8	6
314	Anemia-Induced Bleeding in Patients with Platelet Disorders. <i>Transfusion Medicine Reviews</i> , 2021, 35, 22-28.	2.0	6
315	Pseudo-Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 261-282.	0.0	6
316	Treatment of Heparin-Induced Thrombocytopenia: An Overview. <i>Fundamental and Clinical Cardiology</i> , 2007, , 283-318.	0.0	6
317	The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia. <i>Annals of Internal Medicine</i> , 2022, 175, 604-605.	3.9	6
318	Bacterial infection-associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. <i>British Journal of Haematology</i> , 1995, 90, 332-335.	2.5	5
319	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. <i>British Journal of Haematology</i> , 1997, 97, 762-767.	2.5	5
320	The paradox of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1472-1473.	3.8	5
321	DITP causation: 3 methods better than 1?. <i>Blood</i> , 2010, 116, 2002-2003.	1.4	5
322	A Novel Sickling Hemoglobinopathy. <i>New England Journal of Medicine</i> , 2011, 365, 1548-1549.	27.0	5
323	Hemodialysis-Associated Acute Systemic Reactions and Heparin-Induced Thrombocytopenia. <i>Thrombosis Research</i> , 2012, 129, 405-406.	1.7	5
324	Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 971-973.	3.4	5

#	ARTICLE	IF	CITATIONS
325	Heparin-induced thrombocytopenia in 2017 and beyond. <i>Thrombosis and Haemostasis</i> , 2016, 116, 781-782.	3.4	5
326	Knee replacement and HIT without heparin. <i>Blood</i> , 2016, 127, 961-962.	1.4	5
327	Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. <i>Journal of Pharmacy Practice</i> , 2018, 31, 234-237.	1.0	5
328	Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange. <i>Platelets</i> , 2020, 32, 1-4.	2.3	5
329	HIT: still stringing us along. <i>Blood</i> , 2020, 135, 1193-1194.	1.4	5
330	Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternalâ€”Not Identicalâ€”Twins. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1558-1561.	3.4	5
331	Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Thrombosis Research</i> , 2021, 206, 14-17.	1.7	5
332	Heparin and platelets. <i>Hematology/Oncology Clinics of North America</i> , 1990, 4, 243-64.	2.2	5
333	Immune mechanisms in heparinâ€”induced thrombocytopenia: no evidence for immunoglobulin M antiâ€”idiotypic antibodies. <i>Transfusion</i> , 2009, 49, 1812-1818.	1.6	4
334	Voting with your fondaparinux. <i>Thrombosis Research</i> , 2014, 134, 3-4.	1.7	4
335	Thrombocytopenia Caused by Platelet Destruction, Hypersplenism, or Hemodilution. , 2018, , 1955-1972.		4
336	Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). <i>Blood</i> , 1992, 79, 2480-4.	1.4	4
337	Heparin-induced thrombocytopenia: yet another treatment paradox?. <i>Thrombosis and Haemostasis</i> , 2001, 85, 947-9.	3.4	4
338	Heparin-induced thrombocytopenia and the anesthesiologist. <i>Canadian Journal of Anaesthesia</i> , 2002, 49, S36-49.	1.6	4
339	Argatroban. <i>Drugs</i> , 2001, 61, 523-524.	10.9	3
340	Management of Immune Thrombocytopenia. , 0, , 344-375.		3
341	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. <i>Transfusion</i> , 2012, 52, 1165-1167.	1.6	3
342	Platelet Activation Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Chest</i> , 2016, 150, 478-480.	0.8	3

#	ARTICLE	IF	CITATIONS
343	Colloid Transfusion, Natural Anticoagulant Depletion, and Symmetric Peripheral Gangrene. <i>New England Journal of Medicine</i> , 2020, 383, 1592-1594.	27.0	3
344	Venous limb gangrene and pulseless electrical activity (PEA) cardiac arrest during management of deep vein thrombosis and progressive limb ischemic necrosis following vascular surgery. <i>American Journal of Hematology</i> , 2020, 95, 712-717.	4.1	3
345	Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 1999, 62, 44-48.	4.1	3
346	Prothrombotic genetic risk factors and heparin-induced thrombocytopenia. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 245-246.	5.7	2
347	Lepirudin: walking the dosing line. <i>Blood</i> , 2006, 108, 1428-1429.	1.4	2
348	Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. <i>Biometrics</i> , 2010, 66, 415-425.	1.4	2
349	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver" the unrecognized provocateur of ischemic limb necrosis: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2317-2319.	3.8	2
350	B cells, PF4/heparin complexes, and complement. <i>Blood</i> , 2016, 128, 1781-1782.	1.4	2
351	Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and anti-IgA. <i>Transfusion</i> , 2018, 58, 2320-2325.	1.6	2
352	Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically Ill Patients. <i>Blood</i> , 2009, 114, 3995-3995.	1.4	2
353	History of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 1-20.	0.0	2
354	Letter of response to Peters and Vlaar commentary. <i>Transfusion</i> , 2016, 56, 2395-2397.	1.6	1
355	Sepsis and persisting neutropenia in a drug addict. <i>American Journal of Hematology</i> , 2017, 92, 312-316.	4.1	1
356	Limitations of the particle immunofiltration assay test for diagnosis of heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2020, 95, E250-E254.	4.1	1
357	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1507-1509.	3.8	1
358	Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 autoantibodies at preoperative baseline. <i>Platelets</i> , 2021, , 1-5.	2.3	1
359	Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group. <i>Thrombosis Research</i> , 2021, 207, 62-65.	1.7	1
360	Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder. <i>Blood</i> , 2013, 122, 2328-2328.	1.4	1

#	ARTICLE	IF	CITATIONS
361	Combination Of 4Tâ€™s Score and Rapid Gel Centrifugation Assay Excludes HIT In a Prospective Cohort Study. <i>Blood</i> , 2013, 122, 3535-3535.	1.4	1
362	Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. <i>Thromb Res 2021 in press. Thrombosis Research</i> , 2021, 207, 158-160.	1.7	1
363	Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT).. <i>Blood</i> , 2005, 106, 1234-1234.	1.4	1
364	Acute thrombocytopenia suggesting thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2022, 97, 659-665.	4.1	1
365	How to dose and monitor argatroban for treatment of <scp>HIT</scp>. <i>British Journal of Haematology</i> , 2022, 197, 653-655.	2.5	1
366	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Prävention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. <i>Laboratoriums Medizin</i> , 2011, 35, 45-54.	0.6	0
367	An Instrument-based Immunoassay with an Appropriate Normal Range: Minimizing HIT Overdiagnosis. <i>Thrombosis Research</i> , 2014, 133, 961-962.	1.7	0
368	Safe bridging to warfarin in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 226-228.	1.7	0
369	Management of immune-mediated thrombocytopenia. , 2016, , 245-264.		0
370	Natural, not immune; classical, not alternative. <i>Blood</i> , 2018, 132, 2421-2422.	1.4	0
371	Acquired Thrombocytopenia. , 2019, , 135-148.		0
372	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.9	0
373	Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR.. <i>Blood</i> , 2004, 104, 1845-1845.	1.4	0
374	An Algorithm for â€œIndeterminateâ€•Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT).. <i>Blood</i> , 2006, 108, 1048-1048.	1.4	0
375	Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia.. <i>Blood</i> , 2007, 110, 3214-3214.	1.4	0
376	Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests,. <i>Blood</i> , 2011, 118, 3304-3304.	1.4	0
377	If the Platelets Are Low, Is It HIT?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2019, , 455-479.	0.0	0
378	Diagnosis and Management of Heparin-Induced Thrombocytopenia. , 0, , 158-167.		0